Monday, October 27, 2014 12:43:14 PM
Related Articles
--------------------------------------------------------------------------------
?Plastic surgery
?Blood transfusion
?Surgery
?Laparoscopic surgery
?Robotic surgery
?Vein
The study examined records at the New Brunswick Heart Centre (NBHC) in Saint John for non-emergency heart surgeries performed over almost nine years, from January 2005 to September 2013, on patients who received red blood cells either during their surgery or afterwards and who stayed in hospital less than 30 days.
Of 2,015 patients, just over half (1,052) received only "new" blood, donated within 14 days of the transfusion, while the rest had received only or some "old" blood, donated more than 14 days before. Canadian protocols allow blood to be stored and used up to six weeks after it is donated.
After adjusting for differences in age, sex and other health conditions between the two groups of patients, the study found those given only new blood had fewer in-hospital complications such as re-operation for bleeding, ventilation longer than 24 hours, infection, renal failure and death. Overall the patients who received new blood fared significantly better than those who received some or all old blood.
"The findings show that we need to pay attention to the age of the blood we give cardiac surgery patients," says Dr. Ansar Hassan of the department of cardiac surgery at NBHC, the study's senior author.
Given the benefits to patients of timely cardiac surgery, Dr. Hassan believes surgeries should not be postponed if new blood is not available. "Perhaps more importantly, we need new studies to determine what is driving this relationship between the age of blood and the outcomes we are seeing."
Dr. Hassan notes that previous non-Canadian studies have reached contradictory conclusions on this subject, which was a reason this study was undertaken. The question is important to cardiac surgeons because their work is one of the foremost users of blood products, with 30 to 50 per cent of cardiac surgery patients requiring transfusions. The average cardiac surgery requires five pints of blood.
Heart disease and stroke is the leading cause of hospitalization in Canada, accounting for almost 17 per cent of total hospitalizations. More than 25,000 cardiac surgeries are performed in Canada each year. These procedures -- including coronary artery bypasses, valve replacements and heart transplants -- save and extend the lives of thousands of Canadians every year.
"Cardiac surgery creates heart disease survivors," says Dr. Beth Abramson, Heart and Stroke Foundation spokesperson, author of Heart Health for Canadians. "We need to ensure outcomes are as successful as possible. This study is an important reminder for Canadians to donate blood so that blood products are available for these surgeries."
She reminds all Canadians that 80 per cent of premature heart disease can be prevented with healthy lifestyle choices. "It is possible to reduce our risks with changes to five controllable behaviours: physical inactivity, smoking, stress, poor diet and excessive alcohol consumption."
http://www.sciencedaily.com/releases/2014/10/141027085434.htm
Recent CTSO News
- CytoSorbents May 6, 2024 Virtual KOL and Analyst-Investor Day: STAR-T Pivotal Trial Topline Results & Real World Experience with Antithrombotic Drug Removal in Europe • GlobeNewswire Inc. • 05/02/2024 11:00:00 AM
- CytoSorbents to Report First Quarter 2024 Operating and Financial Results • GlobeNewswire Inc. • 04/26/2024 11:00:00 AM
- STAR-T Pivotal Trial Results to Be Featured as a Late-Breaking Presentation at the 2024 American Association for Thoracic Surgery Annual Meeting • GlobeNewswire Inc. • 04/17/2024 11:00:00 AM
- CytoSorbents to Report Fiscal 2023 Operating and Financial Results • GlobeNewswire Inc. • 03/06/2024 12:00:00 PM
- CytoSorbents to Present at the TD Cowen 44th Annual Health Care Conference • GlobeNewswire Inc. • 02/08/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/17/2024 10:20:45 PM
- Groundbreaking Randomized Controlled Trial Reports Excellent Clinical Outcomes Using CytoSorb® Intraoperatively in Heart Transplant Patients • GlobeNewswire Inc. • 01/17/2024 12:15:00 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 01/08/2024 08:00:03 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/28/2023 09:49:02 PM
- CytoSorbents Provides Update on the STAR-T Trial and Reports Final Independent Data and Safety Monitoring Board Recommendation • GlobeNewswire Inc. • 12/28/2023 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:35:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:34:16 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:34:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:33:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:32:55 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:32:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:31:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:30:43 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/13/2023 02:15:22 PM
- CytoSorbents Announces Closing of $10.3 Million Registered Direct Offering • GlobeNewswire Inc. • 12/13/2023 02:15:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 12/11/2023 09:10:44 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/11/2023 09:10:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/09/2023 09:20:25 PM
- CytoSorbents Reports Third Quarter 2023 Financial and Operational Results • GlobeNewswire Inc. • 11/09/2023 09:15:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:10:54 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM